All Articles

Cord blood offers faster access and lower chronic GVHD but slower engraftment and higher early infection risk than bone marrow.

Umbilical cord hUC-MSCs can regenerate cartilage, lower inflammation, and improve joint function for osteoarthritis with low immune risk and clinical evidence.

Explains multi-layer protections for cord blood: nitrogen cryostorage at −196°C, UPS/generator backups, 24/7 monitoring, GenVault disaster recovery, and data redundancy.

Bank newborn cord blood and tissue to preserve stem cells that can treat 80+ conditions, shorten donor searches, and provide faster access to therapy.

Overview of stem cell approaches for MS—HSCT, MSCs, perinatal cells, and exosomes—clinical trial outcomes, safety and newborn stem cell banking options.

How cord blood stem cells treat rare genetic disorders, improve survival and neurological outcomes, and why banking at birth offers timely access to transplants.

MSC therapies for Crohn's fistulas show ~58% remission at 6 months; adipose and cord-derived cells are promising and generally well tolerated.

Examines clinical trials of stem cell treatments for degenerative disc disease, reporting structural regeneration, pain outcomes, safety, and emerging delivery and cell-free therapies.

Umbilical cord blood and exosomes reduce inflammation, activate satellite cells, and help restore muscle mass and function after aging or injury.